DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneSMAvoice.com | ||
If you'd like to unsubscribe and stop receiving these emails click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscular Atrophy (SMA)
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscular Atrophy (SMA).
Taldefgrobep is an investigational, muscle-targeted recombinant protein with the potential to enhance muscle mass and strength in people living SMA when used in combination with other approved treatments. Taldefgrobep targets myostatin, a natural protein that limits skeletal muscle growth, through two mechanisms: lowering myostatin directly and blocking key downstream signaling mechanisms. Myostatin inhibition is a potential therapeutic strategy for children and adults with a range of neuromuscular conditions for whom active myostatin can limit the skeletal muscle growth needed to achieve developmental and functional milestones.
Related Content
-
People & PlacesBrian G. Smith, MD, FAAP, FAOADr. Smith became the Chief of the Divisi...
-
News & MeetingsDNA From Saliva Has Potential for Detecting SMAA noninvasive method using dried saliva ...
-
EducationSpinal Muscular Atrophy (SMA)Spinal muscular atrophy (SMA) is a genet...
-
EducationThe Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is a rare,...
-
EducationThe SMA France National Registry: Already Encouraging ResultsSpinal muscular atrophy is a debilitatin...
-
News & MeetingsVitamin K Deficiency Caused Blood Clotting Problem in SMA TeenAn adolescent male with spinal muscular ...
-
News & MeetingsSpine Surgery Effective in SMA Type 1 Children, But Not Without RisksSurgery to correct kyphoscoliosis — a ...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email